Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

DEXAMETHASONE FOR SYSTEM SUITABILITY CRS (15 MG)

DEXAMETHASONE FOR SYSTEM SUITABILITY CRS (15 MG)

50-02-2

DISCOVER
TIOTROPIUM IMPURITY MIXTURE CRS (0.08 MG)

TIOTROPIUM IMPURITY MIXTURE CRS (0.08 MG)

NA

DISCOVER
ORPHENADRINE FOR PEAK IDENTIFICATION CRS (0.44 MG)

ORPHENADRINE FOR PEAK IDENTIFICATION CRS (0.44 MG)

341-69-5

DISCOVER
CAPTOPRIL FOR SYSTEM SUITABILITY CRS (20 MG)

CAPTOPRIL FOR SYSTEM SUITABILITY CRS (20 MG)

62571-86-2

DISCOVER
TROLAMINE IMPURITY B CRS (1.5ML)

TROLAMINE IMPURITY B CRS (1.5ML)

111-42-2

DISCOVER
TROLAMINE IMPURITY A CRS (250MG)

TROLAMINE IMPURITY A CRS (250MG)

141-43-5

DISCOVER
ARISTOLOCHIC ACID  I CRS (11 MG)

ARISTOLOCHIC ACID I CRS (11 MG)

313-67-7

DISCOVER
SALBUTAMOL IMPURITY J CRS (0.45 µG)

SALBUTAMOL IMPURITY J CRS (0.45 µG)

NA

DISCOVER
PRAMIPEXOLE FOR SYSTEM SUITABILITY CRS (15 MG)

PRAMIPEXOLE FOR SYSTEM SUITABILITY CRS (15 MG)

191217-81-9

DISCOVER
TIOTROPIUM BROMIDE MONOHYDRATE CRS (15 MG)

TIOTROPIUM BROMIDE MONOHYDRATE CRS (15 MG)

139404-48-1

DISCOVER
Tiotropium for system suitability 10 mg

Tiotropium for system suitability 10 mg

139404-48-1

DISCOVER
GALANTAMINE NATURAL FOR SYSTEM SUITABILITY CRS (10 MG)

GALANTAMINE NATURAL FOR SYSTEM SUITABILITY CRS (10 MG)

04/04/1953

DISCOVER